Indevus: Mixed Results with HIV Blocker

Indevus Pharmaceuticals (NASDAQ:IDEV) says that a clinical study of its anti-HIV microbicide sponsored by the National Institutes of Health showed the treatment was safe but did not show statistically significant benefits. The 3,100-patient study showed that the drug—a vaginal gel applied before intercourse—lowered the risk of infection by 30 percent, shy of the study’s goal of lowering risk by at least 33 percent. The Lexington, MA-based firm expects to reveal results of a larger, 10,000-patient clinical trial of the microbicide by the end of this year.

Trending on Xconomy